10 results about "Immune barrier" patented technology

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The present application relates to the field of food technology, and specifically discloses a composition for reducing gastroesophageal reflux in individuals, a preparation method and application thereof. The composition for reducing gastroesophageal reflux in individuals comprises beta-defensin 1, lysozyme and lactoperoxidase. The present application constructs a multi-target synergistic intervention mechanism combining physical protection, secretion regulation and tissue repair through the compounding of four core components, which can comprehensively block the occurrence and development of gastroesophageal reflux. Lactadherin constructs a physical barrier to reduce the risk of reflux dynamics from the source; MLCT precisely regulates gastric acid secretion to reduce chemical stimulation; HMO complex IgG strengthens the mucosal immune barrier and promotes damage repair. The above composition is applied to products for reducing gastroesophageal reflux in individuals, and multi-target synergistic effect is achieved, realizing a full-chain closed-loop intervention from prevention, relief to repair, and significantly improving the clinical improvement effect.

This disclosure presents a kit for detecting the tumor immune barrier and its application. The kit includes: a first detection reagent that specifically recognizes POSTN protein for labeling POSTN⁺ cancer-associated fibroblasts; and a second detection reagent that specifically recognizes APOE protein for labeling APOE⁺ tumor-associated macrophages. The spatial co-localization characteristics of POSTN⁺ cancer-associated fibroblasts and APOE⁺ tumor-associated macrophages in tumor tissue indicate the presence of the tumor immune barrier. This disclosure achieves high-throughput, automated, and quantitative assessment of the complex spatial structure of the tumor immune barrier (TIB), significantly reducing subjective errors in pathological interpretation and demonstrating good operability and clinical application prospects.

The present application relates to the field of food technology, and specifically discloses a composition for reducing gastroesophageal reflux in individuals, a preparation method and application thereof. The composition for reducing gastroesophageal reflux in individuals comprises lactadherin, medium-long chain triglyceride, human milk oligosaccharide and immunoglobulin G. The present application constructs a multi-target synergistic intervention mechanism combining physical protection, secretion regulation and tissue repair through the compounding of four core components, which can comprehensively block the occurrence and development of gastroesophageal reflux. Lactadherin constructs a physical barrier to reduce the risk of reflux dynamics from the source; MLCT precisely regulates gastric acid secretion, reducing chemical stimulation; HMO compound IgG strengthens the mucosal immune barrier and promotes damage repair. The above composition is applied to products for reducing gastroesophageal reflux in individuals, and multi-target synergistic effect is achieved, realizing the whole-chain closed-loop intervention from prevention, relief to repair, and significantly improving the clinical improvement effect.

The application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis belongs to the field of biomedical technology. This invention addresses the limitations of existing treatments for inflammatory bowel disease (IBD), which suffer from limited efficacy, significant side effects, and difficulty in targeting and repairing the intestinal immune barrier. It provides the application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis. This recombinant ultra-high molecular weight hyaluronic acid can activate the intestinal IgA-producing immune network, regulate inflammation-related genes, and repair the physical and immune barriers of the colonic mucosa, thus exhibiting a superior protective effect against colitis compared to conventional hyaluronic acid, providing a new candidate drug for the treatment of IBD.

This invention belongs to the field of aquaculture biotechnology and discloses the application of a grass carp FGF1 recombinant protein in the preparation of products against Aeromonas hydrophila infection. The amino acid sequence of the recombinant protein is shown in SEQ ID NO:2. This invention is the first to discover that this known protein effectively reduces the pathogen load in tissues such as the liver and spleen by repairing the intestinal mucosal physical barrier (significantly increasing the number of intestinal goblet cells, promoting epithelial cell proliferation, and inhibiting apoptosis) and strengthening the immune barrier (upregulating key antibacterial factors such as IL-22, MUC2, Spla2, and HB-EGFa), and significantly increases the 14-day survival rate of grass carp infected with Aeromonas hydrophila from 10% to 56.67%. This invention overcomes the shortcomings of existing technologies that rely solely on in vitro sterilization or are limited to non-infectious factors, providing a green and efficient biological product solution based on host barrier repair for bacterial diseases in grass carp.

This invention discloses an animal feed containing β-glucan and its preparation method, belonging to the field of animal feed technology. This invention utilizes β-glucan to activate innate immunity, post-biotics to train the immune system, and spirulina to provide immunopolysaccharides and phycocyanin. These three components together form a three-dimensional immune-enhancing network, synergistically strengthening immune function. Furthermore, β-glucan can also function as a prebiotic, inhibiting pathogens and strengthening the immune barrier through the addition of post-biotics, while barley grass powder provides dietary fiber, collectively maintaining intestinal flora balance, optimizing intestinal health, and maintaining the integrity of the physical barrier. Based on improved immunity and intestinal health, combined with balanced nutrition, this improves animal growth performance, especially during stressful periods such as weaning, transportation, and feed changes, promoting growth and stress resistance.

The present application relates to tilapia breeding technical field, especially to a kind of compound additive for enhancing the intestinal barrier function of fragile tilapia.The technical scheme: a kind of compound additive for enhancing the intestinal barrier function of fragile tilapia, including the following components by mass percentage: (A) 2%~15% of targeted physical barrier repair agent;(B) 60%~85% of etiology specific scavenger;(C) 10%~30% of intelligent time sequence delivery carrier, through the trinity design of targeted repair, etiology clearance, intelligent delivery, the pain point of single function of traditional scheme is systematically solved, it not only adjusts flora (biological barrier) by probiotic, more through targeted repair agent actively strengthens tight junction (physical barrier), and through antioxidant component and specific probiotic synergistic maintenance mucosa health (chemical and immune barrier), synchronous, synergistic enhancement to intestinal four barriers is realized, and barrier integrity is significantly improved.

This application discloses the use of deubiquitinase (CYLD) as a biomarker in the preparation of intervention products for late-onset sepsis in preterm infants. The intervention products are used to downregulate CYLD expression or deubiquitination activity to promote intestinal maturation in preterm infants and prevent the occurrence of late-onset sepsis. This application aims to address the challenge of preventing late-onset sepsis in preterm infants due to delayed development of the intestinal immune barrier. Through experiments conducted in three dimensions—mechanism verification, animal efficacy evaluation, and clinical model simulation—this application demonstrates the significant effect of CYLD-targeted intervention products in preventing late-onset sepsis in preterm infants. This invention provides a formulation that downregulates or inhibits the expression of CYLD, a negative immunomodulatory target, to actively induce the maturation of intestinal epithelial cells and strengthen the physical barrier in preterm infants.